The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
News|Articles|June 2, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-06-07-2016
- Volume 11
- Issue 6
ED-XRF Spectrometers Offer Rapid Elemental Analysis
SPECTRO XEPOS spectrometers handle rapid screening elemental analysis and support product quality control at-line for the manufacture of pharmaceuticals.
SPECTRO XEPOS spectrometers from SPECTRO Analytical Instruments feature energy dispersive X-ray fluorescence (ED-XRF) technology for multi-elemental analysis of major, minor, and trace element concentrations. The analyzers are designed to handle critical tasks including rapid screening elemental analysis and support product quality control at-line for a variety of applications including the manufacture of pharmaceuticals.
The spectrometers feature innovations in adaptive excitation plus tube and detector technologies to improve sensitivity by 10´ or more to boost precision, realize lower detection levels, and analyze of a range of elements. The TurboQuant II software analyzes unknown liquids, powders, or solid samples.
The spectrometers remain powered on between measurements to prevent on/off variations from affecting readings and ensure long-term stability.
Optional AMECARE M2M machine-to-machine support extends the analyzers’ self-diagnostic functions with proactive alerts, backed up by direct connection with a remote SPECTRO service PC.
Four versions are available, enabling users to prioritize their selection according to measurement speed, precision, or groups of targeted elements in specific matrices.
Source:
Articles in this issue
over 10 years ago
Slow Serialization Efforts May Delay Business Benefitsover 10 years ago
Scientific Approach Ensures Accurate Weighing Resultsover 10 years ago
Ensuring Biologic API Uniformityover 10 years ago
Biomanufacturing Outsourcing Budgets Grow, Slowlyover 10 years ago
Novasep Starts Kilogram-Scale Batch Production at US Facilityover 10 years ago
FUJIFILM Opens New Laboratory in North Carolinaover 10 years ago
Catalent Opens Korean Sales Officeover 10 years ago
Juniper Pharma Services Expands Topicals Capacityover 10 years ago
Raman Microscope Measures Uneven Surfacesover 10 years ago
Particle Analyzer Based on Light ScatteringRelated to this article
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
Jaenisch, Muraru, and Pandey debate whether AI "slop" is infiltrating pharma SOPs and deviation reports and who should catch it first.
Trending on Pharmaceutical Technology
1
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
2
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
Sweden, a Powerhouse for Early Stage Innovation
5